D
Donald Bunjes
Researcher at University of Ulm
Publications - 240
Citations - 10077
Donald Bunjes is an academic researcher from University of Ulm. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 52, co-authored 227 publications receiving 9183 citations.
Papers
More filters
Journal ArticleDOI
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation.
Christoph Schmid,Michael Schleuning,Rainer Schwerdtfeger,Bernd Hertenstein,Eva Mischak-Weissinger,Donald Bunjes,Stephanie von Harsdorf,Christoph Scheid,Udo Holtick,Hildegard Greinix,Felix Keil,Barbara Schneider,Michael Sandherr,Gesine Bug,Johanna Tischer,Georg Ledderose,Michael Hallek,Wolfgang Hiddemann,Hans-Jochem Kolb +18 more
TL;DR: A sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem cell transplantation (SCT), and prophylactic donor lymphocyte transfusion (pDLT) was studied in 103 patients with refractory acute myeloid leukemia, indicating a high activity of the regimen in refractor AML.
Journal ArticleDOI
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial.
Peter Dreger,Hartmut Döhner,Matthias Ritgen,Sebastian Böttcher,Raymonde Busch,Sascha Dietrich,Donald Bunjes,Sandra Cohen,Jörg Schubert,Ute Hegenbart,Dietrich W. Beelen,Matthias Zeis,Michael Stadler,Justin Hasenkamp,Lutz Uharek,Christof Scheid,Andreas Humpe,Thorsten Zenz,Dirk Winkler,Michael Hallek,Michael Kneba,Norbert Schmitz,Stephan Stilgenbauer +22 more
TL;DR: In conclusion, alloSCT for poor-risk chronic lymphocytic leukemia can result in long-term MRD-negative survival in up to one-half of the patients independent of the underlying genomic risk profile.
Journal ArticleDOI
A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation
Fabio Ciceri,Myriam Labopin,Franco Aversa,Jakob M. Rowe,Donald Bunjes,Philippe Lewalle,Arnon Nagler,Paolo Bartolomeo,João F. Lacerda,Maria Teresa Lupo Stanghellini,Emmanuelle Polge,Francesco Frassoni,Massimo F. Martelli,Vanderson Rocha +13 more
TL;DR: Haploidentical hematopoietic stem cell transplantation can be an alternative option for the treatment of high-risk acute leukemia patients in remission, lacking a human leukocyte antigen-matched donor.
Journal ArticleDOI
Reduced Intensity Conditioning Compared With Myeloablative Conditioning Using Unrelated Donor Transplants in Patients With Acute Myeloid Leukemia
Olle Ringdén,Myriam Labopin,Gerhard Ehninger,Dietger Niederwieser,Richard F. Olsson,Nadezda Basara,Juergen Finke,Rainer Schwerdtfeger,Matthias Eder,Donald Bunjes,Norbert-Claude Gorin,Mohamad Mohty,Vanderson Rocha +12 more
TL;DR: RIC-UD transplants are associated with higher relapse in AML patients younger than 50 years of age and decreased NRM in those > or = 50 years compared with MAC-UD, therefore, RIC- UD extend the use of allotransplants for elderly patients and strategies that decrease relapse should be considered mainly in younger patients with AML.
Journal ArticleDOI
Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis
John Koreth,Joseph Pidala,Waleska S. Pérez,H. Joachim Deeg,Guillermo Garcia-Manero,Luca Malcovati,Mario Cazzola,Sophie Park,Raphael Itzykson,Lionel Ades,Pierre Fenaux,Martin Jädersten,Eva Hellström-Lindberg,Robert Peter Gale,Robert Peter Gale,C.L. Beach,Stephanie J. Lee,Mary M. Horowitz,Peter L. Greenberg,Martin S. Tallman,Martin S. Tallman,John F. DiPersio,Donald Bunjes,Daniel J. Weisdorf,Corey Cutler +24 more
TL;DR: For patients with de novo MDS aged 60 to 70 years, favored treatments vary with IPSS risk, and RIC transplantation offers overall and quality-adjusted survival benefit.